Impairment of GLP1‐induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia
- 28 August 2012
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (s3), 85-90
- https://doi.org/10.1111/j.1463-1326.2012.01648.x
Abstract
One major risk factor of type 2 diabetes is the impairment of glucose‐induced insulin secretion which is mediated by the individual genetic background and environmental factors. In addition to impairment of glucose‐induced insulin secretion, impaired glucagon‐like peptide (GLP)1‐induced insulin secretion has been identified to be present in subjects with diabetes and impaired glucose tolerance, but little is known about its fundamental mechanisms. The state of GLP1 resistance is probably an important mechanism explaining the reduced incretin effect observed in type 2 diabetes. In this review, we address methods that can be used for the measurement of insulin secretion in response to GLP1 in humans, and studies showing that specific diabetes risk genes are associated with resistance of the secretory function of the β‐cell in response to GLP1 administration. Furthermore, we discuss other factors that are associated with impaired GLP1‐induced insulin secretion, for example, insulin resistance. Finally, we provide evidence that hyperglycaemia per se, the genetic background and their interaction result in the development of GLP1 resistance of the β‐cell. We speculate that the response or the non‐response to therapy with GLP1 analogues and/or dipeptidyl peptidase‐4 (DPP‐IV) inhibitors is critically dependent on GLP1 resistance.Keywords
This publication has 35 references indexed in Scilit:
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?Diabetologia, 2010
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?Diabetes, 2010
- Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose toleranceAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Incretins, insulin secretion and Type 2 diabetes mellitusDiabetologia, 2004
- Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjectsRegulatory Peptides, 2003
- The Influence of GLP-1 on Glucose-Stimulated Insulin SecretionDiabetes, 2003
- Clinical Characterization of Insulin Secretion as the Basis for Genetic AnalysesDiabetes, 2002
- Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretionDiabetologia, 2000
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.JCI Insight, 1993
- Reduced incretin effect in Type 2 (non-insulin-dependent) diabetesDiabetologia, 1986